Woman with ALS explains "Medical Aid in Dying" decision: "I don't want more time as a patient"
When CBS News visited Barbara Goodfriend's home in New Jersey, it was crowded with family and friends — a place that seemed full of life. So it was hard to process that it was also a place where she was determined to die just 24 hours later.
"It's been a week of family, friends. We've done a lot of crying, all of us, but we've laughed. We've enjoyed being together," Goodfriend said.
Last April, Goodfriend was diagnosed with ALS, or Amyotrophic Lateral Sclerosis, a disease that attacks the nervous system and robs people of their muscle control. The 83-year-old widow spent decades working in fashion while raising her only daughter. After a doctor told her she might not live through the fall, she deteriorated quickly and suffered falls that caused bruises on her face.
Rather than suffer, Goodfriend has chosen what's known as "Medical Aid in Dying," or MAID. A doctor prescribes a mixture of lethal medication. The patient must have six months or less to live, be of sound mind and must administer it themselves. The procedure is different than euthanasia — when a doctor gives a patient a lethal injection — which is illegal in the U.S.
Goodfriend says she doesn't want to die, but she also doesn't want to continue living with a terminal disease.
"What am I going to give this up for? To be in a wheelchair? To have a feeding tube? I wish I had more time to live, but I don't want more time as a patient," Goodfriend said. "I hope that something will get done, something will be accomplished, so that others can have the privilege that I'm having."
Dying with medical assistance is currently legal in 10 states and Washington, D.C., but eight other states are considering similar laws this year, according to the nonprofit Death with Dignity.
Dr. Robin Plumer has attended nearly 200 deaths in New Jersey, where MAID was made legal in 2019. The law doesn't require Goodfriend to have a doctor at her bedside on her final day, but she wanted Plumer there.
"You're going to drink this medicine and drift off into sleep and you're going to just feel all the love and support," Plumer said.
Goodfriend says no one tried to talk her out of it. Her daughter, Carol, helped her through the process.
"I think the hardest part in all of this, for me as her only child, is to support something so difficult and so contrary to what you want to do. The ultimate love that you can give somebody is to respect their wish, to live the way they wanna live, and to die the way they want to die," Carol said.
Goodfriend's last day of life was spent with her loved ones in a room full of unmistakable emotion. But the calmest one there was the woman in bed who'd made the choice to die.
"I'm not afraid of dying...I was afraid of living," Goodfriend said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 days ago
- Business Upturn
Parse Biosciences GigaLab to Support Mount Sinai Researchers in Generating One of the Largest Alzheimer's and Parkinson's Single Cell Datasets
Seattle, United States: Parse Biosciences today announced their commitment to support researchers from the Icahn School of Medicine at Mount Sinai in generating one of the largest single cell datasets focused on understanding alternative splicing events in the cells of Alzheimer's and Parkinson's patients. The study's initial phase will analyze transcriptomic profiles from more than 10 million cells derived from more than 1,000 peripheral blood mononuclear cell (PBMC) samples of patients with neurodegenerative conditions. The data amassed from these analyses will lay the foundation for discoveries that could transform how these diseases are understood, detected, and treated. 'Historical research in neurodegenerative disease has focused on the genomic underpinnings for disease diagnoses, but few have looked at the post transcriptional events that may be further driving pathology and progression of disease,' said Towfique Raj, PhD, principal investigator in the laboratory for functional genomics and core faculty member of the Ronald M. Loeb Center for Alzheimer's Disease at Mount Sinai, who will lead this study. 'We're excited to be able to look at alternative splicing events in single cells at scale to determine alternative contributors to disease onset, progression and severity. Studies of this scale are critical to the development of foundational models to help us better understand neurodegenerative disease.' Dr. Raj's research team at Mount Sinai is dedicated to understanding the molecular mechanisms of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and ALS (amyotrophic lateral sclerosis). For this study, the Mount Sinai team is working to conduct high-throughput profiling on banked PBMCs donated by patients with confirmed Alzheimer's disease or Parkinson's disease diagnoses. The researchers expect to profile more than 1,000 samples in order to capture single cell whole transcriptome repertoire data on them. The samples that have been prepared at Mount Sinai will then be sent to Parse GigaLab, a state-of-the-art facility purpose-built for the generation of massive-scale single cell RNA sequencing datasets. Leveraging Parse's Evercode chemistry, the GigaLab can rapidly produce large single cell datasets with exceptional quality. 'We are incredibly excited to bring the power of GigaLab to elevate the impactful work the Raj Lab has been driving,' says Dr. Charlie Roco, Chief Technology Officer at Parse Biosciences. 'The speed and scale achieved with the GigaLab truly helps to accelerate research and get us to insights faster than we ever have before.' About Parse Biosciences Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by over 2,500 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Parse Biosciences is based in Seattle's vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
3 days ago
- Yahoo
Once named opponents in the Supreme Court case that legalized same-sex marriage, now they're friends
COLUMBUS, Ohio (AP) — The case behind the U.S. Supreme Court ruling legalizing same-sex marriage nationwide a decade ago is known as Obergefell v. Hodges, but the two Ohio men whose names became that title weren't so at odds as it would seem, and are now friends. One year after the Supreme Court's June 26, 2015, decision, lead plaintiff Jim Obergefell was at an event for an LGBTQ+ advocacy organization when its former director asked if he wanted to meet Rick Hodges, who'd been the title defendant in his capacity as state health director in Ohio, one of the states challenged for not allowing same-sex couples to marry. 'I don't know, you tell me. Do I want to meet Rick Hodges?" Obergefell recalls responding. The two met for coffee in a hotel and hit it off. Hodges said he wanted to meet Obergefell because he's an 'icon.' He said he remembers telling Obergefell something along the lines of: 'I don't know if congratulations are in order because this began with you losing your husband, but I'm glad you won and I've never been so happy to lose in my life.' Obergefell and John Arthur, who brought the initial legal action, were longtime partners living in Cincinnati. After Arthur was diagnosed with ALS, or amyotrophic lateral sclerosis, in 2011, Obergefell became Arthur's caregiver as the incurable condition ravaged his health. They flew to Maryland to marry before Arthur died in 2013, and the legal battle began when they learned their union wouldn't be listed on the death certificate handled by the Ohio Department of Health. Although Hodges' role as health director required him to defend the state, it didn't mean that his personal views aligned with the state's position. 'Personally, I was supportive of their efforts, as were some of the people who worked on the case for the state. Professionally, I had a job to do and I did it to the best of my ability," Hodges said. In the months leading up to the court's decision, Hodges had gathered a group of Ohio lawyers to develop the paperwork needed to create the licensing system for judges to grant same-sex couples marriage licenses on the day of the decision if the Supreme Court ruled in their favor, said Obergefell's lead attorney in the case, Al Gerhardstein. Gerhardstein said Obergefell and Hodge's friendship is unusual in a 'very positive and exemplary way.' 'We need more models like that as we struggle with difficult social issues," he said. The duo said they see each other two to three times per year and have routinely spoken together at conferences and panels. 'It's funny, whenever we go into an event together, everybody claps for him and looks at me like I'm the prince of darkness until we're done, and then it's great," Hodges said. They are seeing each other more often this year since it's the 10th anniversary of the decision. Recently, they saw each other at a symposium at Northern Kentucky University and at another event, sponsored by Equality Ohio, the same organization that first led to their introduction. 'I can't think of other cases where the plaintiff and the defendant are friends. They might exist, I don't know about them," Obergefell said. "But I'm really glad that Rick and I are friends.'
San Francisco Chronicle
4 days ago
- San Francisco Chronicle
Once named opponents in the Supreme Court case that legalized same-sex marriage, now they're friends
COLUMBUS, Ohio (AP) — The case behind the U.S. Supreme Court ruling legalizing same-sex marriage nationwide a decade ago is known as Obergefell v. Hodges, but the two Ohio men whose names became that title weren't so at odds as it would seem, and are now friends. One year after the Supreme Court's June 26, 2015, decision, lead plaintiff Jim Obergefell was at an event for an LGBTQ+ advocacy organization when its former director asked if he wanted to meet Rick Hodges, who'd been the title defendant in his capacity as state health director in Ohio, one of the states challenged for not allowing same-sex couples to marry. 'I don't know, you tell me. Do I want to meet Rick Hodges?" Obergefell recalls responding. The two met for coffee in a hotel and hit it off. Hodges said he wanted to meet Obergefell because he's an 'icon.' He said he remembers telling Obergefell something along the lines of: 'I don't know if congratulations are in order because this began with you losing your husband, but I'm glad you won and I've never been so happy to lose in my life.' Obergefell and John Arthur, who brought the initial legal action, were longtime partners living in Cincinnati. After Arthur was diagnosed with ALS, or amyotrophic lateral sclerosis, in 2011, Obergefell became Arthur's caregiver as the incurable condition ravaged his health. They flew to Maryland to marry before Arthur died in 2013, and the legal battle began when they learned their union wouldn't be listed on the death certificate handled by the Ohio Department of Health. Although Hodges' role as health director required him to defend the state, it didn't mean that his personal views aligned with the state's position. 'Personally, I was supportive of their efforts, as were some of the people who worked on the case for the state. Professionally, I had a job to do and I did it to the best of my ability," Hodges said. In the months leading up to the court's decision, Hodges had gathered a group of Ohio lawyers to develop the paperwork needed to create the licensing system for judges to grant same-sex couples marriage licenses on the day of the decision if the Supreme Court ruled in their favor, said Obergefell's lead attorney in the case, Al Gerhardstein. Gerhardstein said Obergefell and Hodge's friendship is unusual in a 'very positive and exemplary way.' 'We need more models like that as we struggle with difficult social issues," he said. The duo said they see each other two to three times per year and have routinely spoken together at conferences and panels. 'It's funny, whenever we go into an event together, everybody claps for him and looks at me like I'm the prince of darkness until we're done, and then it's great," Hodges said. They are seeing each other more often this year since it's the 10th anniversary of the decision. Recently, they saw each other at a symposium at Northern Kentucky University and at another event, sponsored by Equality Ohio, the same organization that first led to their introduction. 'I can't think of other cases where the plaintiff and the defendant are friends. They might exist, I don't know about them," Obergefell said. "But I'm really glad that Rick and I are friends.'
